Вы находитесь на странице: 1из 81

2008

()
...................................................................................................... 3
- () .............. 12

( ) ........ 21
........................................... 29

................................................................................. 39
......................................................................... 48
.............. 56
()
................................ 64
- ............................... 70
........................................................ 76

..

()

.. , .. , ..

. .. .. ,
,
, ,

( )

- ,
- ,
. ,
.

. . , .
(), 1977 .

Lactobacillus bulgaricus.

. . .

4
,
, , .
. .. ..
.

() .

.

1996 .


: (Likopid)
: N--(14)-N---D- (). :
C27H45N5O16. : 695 . , ( 1 /).
H 4,2 ( 1 10-3 /) pK 5,48. . :

GLcNAc(14)Mur NAc
CH2OH
HO
HO

CH2OH

O
NAc
H

OH

O
O

H3C

NAc
H
CH3

N
H

ALa

H
N

COOH
CONH2

D-iGLn

..

: ,
0,1 , 0,01 0,001 . 10
.
: 5 .
: ( ) , , .
: , :
(N--N- ) Micrococcus lysodecticus,
(-D-), . ,
GMP (Good Medical Practice).



, - , .

.
,
.
, -,
,
.
NOD2 . NOD2- , , /, ,
,
.

6
NOD2- , NF-kB.
, , , . , ,
(, , ,
)
- -. , - .
.
, ,
(, , )
.

b
b

l
l

/,

r


, .

..


-450 ( ), () .

:
LD50 7000 /.
: 28 , - : 1,0 /
0,5 / 2,1 / .
- : , 50100 ,
-
.
: , .
: , 1000 ( 50 /), .
: ,
.
: 57 .
50 (0,7 /) .
30-50 .
, ,
.


(
), ( ) 14- (14-).
,
120 . 14- 8 ,
. .
14- 76,7%.
14- : 1,7 ,
.
-
: 112 . 14-
,
. 14-
6,7%.
14- , , (13%).
14- 4,5 .


per os 83%.
. max
1,5 . .
, .

..


, , , , .
. .
.



1000
-
. . - , , ,
, , (), ,
- .
GCP (Good Clinical Practice), .
,
,
.
. 1995 .
(
95/211/4). 1998 . , , .

10

,
, - .
,
-
. ,
.

.
- (
, , - , ), (-
, ).

. ,
, , , .
:
;
;
-;
.

..

11


, .
, , , , .
.

12



()

.. , .. , ..
,

. .. .. ,
, ,

,
1796 ,
. ()
(, , 1890 .) . . , 1893
,
-.
894 45%-
. , , .
,
30- -

..

13

.

( ),
.
.
.
, , , ,
, -, . ,

, .

100- .
,

, ,
.
, 80-

, ,
() () .
, , .
, .

14





,
.
. ,

()
,
, .
, (. 1).
1.



I.
-
1.
2. -
3. -
II. () -
,
)
1. (-,
, -2)
2. (, ,
, ,
, )

..

15

() ;
I.
(, ,
.)
II.
(- -,
-)


- -.
, ( ).

, , .

, .
. 15
() . - , , .
, ,
. , ,

16
, ,
.

,
, (). ,
,
. ,
: (per os, ), ( ), ,
.



in vitro in vivo

.
(. 2).
2.

(%)

S-180

60

Meth

50

-37

50

S-298

50

50

-16

50

-755

28

LLC

30

..

17


, .
,
.
(. 1). , - , .
NOD2-, Toll-
- . NOD2- , , /,
, , ,
.
NOD2-
,
NF-kB.
, , , . , ,
(, ,
, , )
- -.
- , - ().
, , Toll- (, ).
, ,
(, , ) .

18

1.

+
(%)


.
- , .
2.
60

40

150 /
500 /

20
0
-20
6
24
36
48

2. BRO-

,
, . ,

..

19

(3)


. , ,
. , +
. 3.

( )
23

10

21,5
23,6

7,5
5

33,2

2,5
0

10

15

20

25

3.
LLC

, ,

.
, , -1. ,
,
(
),

.
, ,
4- :

20


-

[1] - B.C. . -
1982, 1983, 1984 .
[2] Andronova ., Ivanov V. The structura and immunomodulating function of
glucosaminylmuramyl peptides. Sov. Medical Review D. Immunology 1991, 4, 1-63.
[3] Girardin S.E., Travassos L.H., Herve M., Blanot D., Boneca I. G. et al. Peptidoglycan
molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 2003,
278 (43), 4170241708.
[4] Nesmeyanov V.A., Khaidukov S.V., Komaleva R.L., Andronova T.M., Ivanov V.T.
Muramylpeptides augment expression of Ia-antigens on mouse macrophages.
Biomedical Science 1990, 1, 151-154.
[5] Ogura Y., Inohara N., Benito A., Chen F. F., Yamaokai S., Nunez G. Nod2, a Nod1/
Apaf-1 family member that is restricted to monocytes and activates NF-kB. J. Biol.
Chem. 2001, 276 (7), 48124818.
[6] Petrova E.E., Valyakina T.I., Simonova M.A., Komaleva R.L., Khaidukov S.V., Makarov
E.A., Blokhin D.Y., Ivanov P.K., Andronova T.M., Nesmey-anov V.A. Muramyl
peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with
cytotoxic drugs on tumor cells. Int. Immunopharmacol. 2006, 6 (9), 1377-1386.
[7] Shimizu T., Iwamoto Y., Yanagihara Y., Ikeda K., Achiwa K. Combined effects of
synthetic lipid A analogs or bacterial lypopolysaccharide with glucosaminylmuramyl
dipeptide on antitumor activity against meth A fibro-sarcoma in mice. Int.
Immunopharmacol. 1992, 14 (8), 1415-1420.
[8] Utsugi ., Schroit A.J., Connor J., Bucana CD., Rider I.J. Elevated expres-sion
of phosphatidylserine in the outer membrane leaflet of human tumor cells and
recognition by activated human blood monocytes. Cancer Res. 1991, 51, 3062-3066.
[9] Vasselon T., Detmers P.A. Toll receptors: a central element in innate immune responses.
Infec. Immun. 2002, 1033-1041.
[10] Waldmann T.A. Immunotherapy: past, present and future. Nature Med. 2003, 9 (3),
269-277.

. ..

21





(
)

-

. ..

.
,
,
, .
,
. - ,
,
, ,
.

, .
: (-),
- (-), , -

22
-1 (-1), .
.
, :
1.
50% ,
20%
2.
3.

.
, - ,
. , , .
, , , : -1,
, , , ,
- , .
. .. .. N-(14)-N---D-,
.
.


29 , , - . .. ,
2 :

. ..

23

1 (n=15), .
2 (n=14),
.
1 II-III (93% )
; 2 I-II (86% ) .
2 ( )
10 10 ( 200 ).
.
, , .
3, 5, 7 10 .
- .
p<0,05.



, . ,

, .

.
.

24
1. ,
(1 )

, %

1

7-10

27

47

II

53

20

III

27

IV

13

(1) , - .

1, 93%
II-IV .
2,00,2109 / ( 4,0-9,0x109
/ ), 2 . ( 2). , 1,20,2109 / ( 2,0-5,8x109 /), 0,50,08x109 /
( 1,2-3,0x109 /).
:
1,8 .
27% , 47% I , (93%) II-IV . II-III 26%
, IV
.

. ..

25

2. , (1 )

, , , ,
109 /
109 /
109 /
109 /


1 (n=15)

2,00,2

1,202

0,160,03

0,50,08

4-5
(n=11)

2,90,3*

1,90,3

0,270,05

0,80,09

8-10
(n=12)

3,50,2*

2,10,2*

0,220,01

1,00,1*

4,0-9,0

2,0-5,8

0,09-0,6

1,2-3,0

()
(*)
(1) , -


, 1,8 2,10,2x109 /,
2,0 1,00,1109 /. , 1
.
, , , ,
, , , 10- III-IV I-II.
3 4 , (2 ).

26
3. ,
(2 )

, %

7-10

7 (n=1)

27

21

46

II

65

27

III

IV

4. , (2- )


109 /
109 /
109 /
109 /


(n=14)

2,40,2

1,80,2

0,130,02

0,60,04

4-5
(n=11)

2,60,3

1,80,4

0,180,02

0,50,08

8-10
(n=9)

3,70,4*

2,90,3*

0,320,06*

0,50,08

4,0-9,0

2,0-5,8

0,09-0,6

1,2-3,0

()
(*)



I-II . 4, 2,40,2109 / ( 4,0-9,0),
1,80,2x109 / ( 2,0-5,8109 /) 0,60,04109 /
( 1,2-3,0x109 /), .

. ..

27

I-II . -, , I-II ,

, .
.
, ,
,
. 7-10 73% I-II , 27%
. 7-10
.
3,70,4109 /.
,

70% ,
20% .
2,90,2x109 /.

8% 2 , , ,
, .
69% , .
.
.

28

1. III-IV , ,
, .
2. I-II ,
, , .
3.

.. , ..

29

.. , ..


. ,


[6, 10, 11]. , , [4, 9].
[1, 3-5].
- (n = 228) - (n = 246) 1996 2001 .

.
: 1)
()
10-15 ; 2)
; 3)
; 4)

30
; 5) - .
-
.
, , . -
,
.
.

.
.
, 58,8%
.
52,2%, 10,5% . 14%, 7,5%.

60 (57,4%) (48,3% 40-60 ), , , .
: 40-60 6,7%,
60 8,7%.

60 19,4% ( 40-60 9,2%).
,
, ,
, .
( ) 77,6%.
-

.. , ..

31

40-60 73,3%, 60 69,4%.


, , , , , (, ,
), , , .
, .
.
. ,
-
() 75,2% . 58,5%. 7,3% , 9,3%. 8,5% ,
0,8% .
, , .

.
, CD3+,
CD4+, CD8+, CD4+/CD8+, CD16+, CD22+.
(, , G). ,
() .

T- CD4+, CD4+/CD8+.
Th2-.
CD16+- .

32

1. (n = 228)


(. 1).
.
. CD3+, CD4+, CD4+/CD8+,
.
( IgA)
(. 2).

, .
,
-

.. , ..

33

2.
(n = 246)

,
. , ,
. ,
(, , , .),
:
T- ,
Th2-;
;
.
, ,

34
(, , ) - .
- ,
.
.
.
(n = 93)
( 10
1 7-10 ). 2

.

CD3+, CD4+, CD4+/CD8+, ,
. : - , ,
, ,
.

.

.

.. , ..

35

3. ,
( n = 78)

-

70 (10 1 7 )
[2, 7, 8]. - 3
:
(n = 82), 1
(n = 86) 2 70 10- (n = 78). , , , 100-
( )
(. 3).

36

4. , 1
(n = 86)

, 1 , , (. 4). - 100-
( ) ,
2 .

,
(. 5).
, ,
, , ,

.. , ..

37

5. , 2
(n = 78)

.
.

1. 3 4
(77,6 75,2% ), .
2.
( 71,5%, 58,5%).
3.
.

38
4.
.
5.
.
6.
- .
7.
: 70
(10 1 7-10 2- ).

[1] .., .., .., .. // . . .


1998. 23. . 8687.
[2] .., .. // Terra Medica. 1999.2. . 2829.
[3] .., .., .., .. // I
. , 36 1996 . ., 1996. . 145.
[4] .., .., .. . // . . .
1997. 6. . 911.
[5] .. // . . 1998. . 44, 1. . 120125.
[6] .., .., .. . // . 1995. 1 . 1318.
[7] .., .., .. // Medical Market. 1996. 56. .
1013.
[8] . ., .., . . // . 1998. 1. .
4651.
[9] Biologic therapy of cancer // De Vita V.., Hellman S., Rosenberg S. A. et al.
Philadelphia, 1995.
[10] Sounders C. The Management of Terminal Malignant Disease. 1993.
[11] Twycross . Introducing Palliative Care. Oxford; New York, 1995.

..

39




.. , .. , .. ,
.. , ..

,


. -, ,
, ,
,
[Steller E.., 1988; Hayakawa ., 1990].
,
, [Nanbara S., 1989;
Colborn D., 1989].
, ,
.
, ,
(-, - -, ).

40
. -
[Dziarski R., 1988]. in vitro ,
, ,
[Chedid, 1983].
()
,
[Balitsky K.P., 1989].
() , [Miknailova A.A.,Petrov R.V.,1988].


32
IV , ,
. (- ) 31 ,
. 25 (80,6%)
. 3 (9,4%)
. 3
. .
, 1 . :

..

41

1- (13 ) () ( . .. , ) 1 3
per os, 10 ( 30 ).
2- (14 ) ( , ) 3
, , 5 ( 15 ).
3- (5 ) () 10 /,
90 , .
2-3 .
3-4 .

106/

. ,
per os, ,

(. 1).
10000
8000

1
2

10000

8000

6000

6000

4000

4000

2000

2000

1.

42
, CD3+, CD4+ CD21+ ,
, (. 2).

70
60
50

1 CD3+
2 CD4+
3 CD8+
4 CD21+
5 CD16+
6 HLA-DR+

70

60

50

40

40

30

10
2

20

30

20

10

2.

, (. 3). ,
()
,
. , ,
,
, .


. 1- ,
, ,
(. 4).

..

43

100000

100000

80000

80000

60000

60000

40000

20000

40000

20000

3.

1 3-
2 3- (72 )
3 3- (72 )
4 3-
(72 0% )

40

40

20

20

100

100

80

80

60

60

4.

44

Ig , , IgG (. 5).

1200

1200

1000

1000

800

800

600

600

400

200
1

400

2

1 IgA
2 IgM
2 IgG

200
3

5.

, , per os,
.
, ,

. ( 3- )
,
, , , ,
(, ), .
,
. 4- ,
10 ,

..

45

12000
8000

4000

1
2
.
1 CD3+
2 CD4+
3 CD8+

4 CD21+
5 CD16+
6 HLA-DR+

100
50


0
1
2
3
4
5
6
.

100

50
0

1
2
.


106/

1
2

( 2 )
). ,
,
. ,
, .
7
.
,
.
, per os.

120000
80000

1
2
3
4 +

40000



1
2
3
4
.

6.

46
, CD4+,
CD21+, CD16+ ,
(. 6). . .
[Khaitov
R.., 1992].
, ,
.
,
. ,
, .

- , - ,
, - .

[1] Hayakawa M., Sisido S., Higa I., Hatano T., Osawa A. Study on adoptive immunotherapy
with tumor infiltrating limphocytes (TIL) for renal cell carcinoma application of IL-2
elected TIL proliferation by OKT-3 monoclonal antibody. Nippon Hinyokika Gakkai
Zassi, 1990, 81, 103-109.
[2] Nanbara S., Arinaga S., Akiyoshi T. Augmentation of generation of limphokine
activated killer cells after a single doses of mitomycin C in cancer patients. Cancer
Immunol. Immunother., 1989, 29, 237-241.

..

47

[3] CoIborn D., Rinehart J., Zwilling B., Irr J. Expansion of limphokine activated killer
cells for clinical use utilising a novel culture device. J. Immunol. Meth., 1989, 119,
247-254.
[4] Steller E.P., Ottow R.T., Eggermont A.M., Marguet R.L., Sugarbaker P.H. Local
conditions in the host influence immunotherapy with interleukin-2 and LAK-cells.
Cancer Detect. Prev., 1988, 12, 81-90.
[5] Chedid S.L., Morin A., Phillips N. Potential use of muramilpeptide in cancer therapy
and prevention. Bacteria and Cancer, 1983, 8, 49-86.
[6] Dziarski R. Enchancement of B-cell stimulation by muramyl peptide through a
mechanism not involving interleukin 1 or increased Ca++ mobilisation or protein
kinase C activation. Cell. Immunol., 111, 10-28.
[7] Khaitov R.M., Luss L.V., Prokopenko V.D., Poroshina Yu.A., Fedenko E.S., Latysheva
T.V., Polsacheva O.V. Extracorporal methods of therapy in allergic diseases. Allergy &
Clinical Immunology News, 1992, 4, 11-15.
[8] Balitsky K.P., Umansky V.Y. Glucosaminilmuramildipeptide-induce changes in murine
macrophage metabolism. Int. J. Immunol., 1989, 11, 429-434.
[9] Mikhailova A.A., Petrov R.V. Regulation role of the bone marrow in the immune
response and bone marrow mediators (myelopeptides). Sov. Med. Rev. D. Immunol.,
1987, 1, 151-237.

48





.. , .. , ..

. 20-200 100000
, [2, 3].
, [1].
: .


93 , 43 78 . .

. (CD3+, CD4+,
CD8+, CD20+, CD56+). (Ig, IgM, IgG), (),
.

.. , .. , ..

49

,
, .

,
10-14
.

2 : .
(n=39)
,
. 1 2 10 . (n=54)
, ,
. ,
, , .

, ,
( 4-6
).

50
,
( - ).
- :
- (1002120 /), - (51278 /)
(1,10,08).

( , ) - (132,4%).
(21829 ..).

.

,
.

, . 500 . / 4 10 .

1 2 10 .
, 5-7
, , . , ,
,
(. 1).

.. , .. , ..

51

1.
( 7- )


(n=39)
.
%
31*
79,5
25*
64,1
31*
79,5

(n=54)
.
%
21
38,9
17
31,5
21
38,9

33*

84,6

24

44,4

27*

69,2

16

29,6

29*

74,4

19

35,2

: *<0,001
.

7-10 ( 18-21 ).
, , . , -
: - (CD3+), - (CD4+), (CD4+/CD8+).
: 20,5% ( 66% 83%,
<0,02);
( HCT-).

- :
, (
-), .
- ,
.

52
,
- ,
. , ,
.
, - ,
, ,
, ,

. , ,

.
20 , 1 ,

(1 10 , , 10 ).
, , (n=19)
,
.

. 10-14 .
, (55,0%)
, , . .

.. , .. , ..

53

, , .
(45,0%)
- (CD3+) - (CD4+) ; -.
( 835,1%, <0,01) .
(10821 ..).
, 1 () (n=19), . ,
(764,3%) ( -: 223,1%),
(14924 .).
, ,
. - (5060320 /) (1680188 /), -
(1002140 /). (56484 /)
(28,11,8%) - (1,20,09),
( : 634,1%, P<0,01) -.
, 10-14
, 2 ( ).
4-6 .
,
, , , 1,2 .

54
51
(94,4%). 19 (37,3%). 2,
3 , 28 (54,9%).
(n=39) 7
(17,9%; <0,05). , , , . ,
19 , ,
4 (21,1%),
2 . , 6 (31,6%).
20 , , 3 (15,0%),
(<0,05) , .
, 5 (25,0%, <0,02).
,
,
.

:
1. ,
.
2.
.
- (CD3+, CD4+)
.

.. , .. , ..

55

3.

.

[1] .., .., ..


// . - 2001. - 1. - . 18-20.
[2] .. //
3- . , 1992 . , 1992. - . 2. - . 267-270.
[3] .. . // .: , 1986.

56

M.. , .. , .. ,
.. , ..
,
,

,
,
,
-,
-, -,
, ,
.
.

.
,
, , ,
[1, 3, 4].
80- , , -

M..

57

. , . -
, [5].
. . ,
(, , ). ,
, per rectum,
-2.

.


96 ,
. 53,61,3
. , TNM
(1985). .

. IB, I, II, III
. 4
3 . IIIB ( ),

58
, - -.
3 .
12- 10 20 -2 500000 ME 2 20 , IIIB

.
1 10 , . .

. , (CD3+, D4+, CD8+,
CD19+), , .


,

, ,
(. 1 2, ).
, , , (<0,05), ,
. . - (CD19+),
- (CD3+) (CD4+, CD8+), CD4+/CD8+. , , .
+ +
-

M..

59

(. 1 2). ,

, , -. CD3+, CD4+ CD8+ , +
+ , , ,
. ,
CD4+/CD8+.
I . - ,
.
, , , IgM
, ,
. IgG IgA .
,
, , .
,

. ,
( , , , , ) , , 37% ,
, ,
23% 25% . , , ,
29,7% , 23% 19,8%

60
1. + +

IA

IB

IC

II

IIIA

IIIB

, 109 /

1,50,1

1,40,1

1,20,1

1,00,1

0,90,1

0,70,1

2,50,3*

2,30,2*

2,00,2*

1,70,2*

1,50,2*

1,30,1*

2,00,2*

1,90,2

1,70,2*

1,50,2*

1,30,1*

1,20,1*

38,03,7

33,03,2

27,44,1

- (CD3+), %

49,14,5

43,03,7

40,33,3

69,36,7* 65,16,5* 63,06,3* 56,05,6* 51,25,0* 49,05,0*

+ 64,06,4* 62,26,2* 60,16,0* 55,35,5* 52,15,2* 49,04,9*


- (CD4+), %

30,02,9

45,74,0* 43,24,1* 42,64,0* 37,43,7* 35,33,5* 33,13,3*

+ 39,13,9

28,12,3

27,02,2

25,21,9

22,02,5

18,01,6

37,43,7 36,03,6* 33,03,3* 31,23,0* 30,13,0*

- (CD8+), %

19,01,9

15,01,3

13,11,1

13,00,6

11,20,7

19,01,3

24,12,5* 22,32,2* 21,22,0* 19,91,9* 16,81,6* 16,91,5*

+ 25,32,5 25,02,5* 24,12,4* 22,42,2* 21,12,0* 19,02,0*


- (CD19+), %

13,01,1

18,61,8* 16,51,6* 16,11,6* 15,31,5* 14,11,4* 14,01,4*

+ 16,11,6

12,01,2
15,01,5

12,01,5
14,31,4

10,01,1

9,00,7

7,00,5

13,11,3 12,41,2* 12,31,2*

: (*) ( ,
) (<0,05).

. 47%;
, + + ,
31% 34% .

M..

61

2. + +

IA

IB

IC

II

IIIA

IIIB

+e

0,70,1

0,60,06

0,50,05

0,60,06

0,50,05 0,60,06

1,9*0,2* 1,90,2*

1,80,2*

1,80,2*

1,60,2*

1,50,2*

+ 1,480,1* 1,440,1* 1,400,1* 1,370,1* 1,290,1* 1,230,1*


-, %

30,02,9

33,03,2

19,01,9* 21,02,0* 24,02,3* 28,02,8* 37,03,7* 39,03,9*

+ 24,02,5* 28,02,5

38,04,1
33,03,0

41,04,7

47,03,7 53,05,1

36,03,5

38,03,5 43,04,0*

17,31,5

15,91,9

15,11,5 14,81,5

Ig,

20,52,1

17,51,8

19,71,9

19,11,9

18,01,9

16,01,5

15,01,5 15,01,5

+ 21,02,0

21,02,0

19,01,9

16,01,5

15,01,5 14,01,3

1,20,3

1,00,1

0,80,07 0,70,08

Ig,

1,30,1

1,20,1

1,90,2*

1,70,1*

1,60,1

1,60,1*

1,50,1*

1,40,1*

+ 1,80,2*

1,60,2

1,60,2

1,40,3

1,20,1*

1,20,1*

IgG,

85,78,3

83,98,1

85,53,9

86,37,5

85,35,5 83,58,7

96,09,1

94,09,4

93,09,3

90,09,3

87,08,7 85,08,5

+ 94,09,4

91,09,0

91,09,0

87,08,7

84,08,1 84,08,1
78,03,2 78,03,1

, %

90,03,7

87,02,4

85,02,5

83,01,5

93,04,1

91,03,1

90,03,0

90,02,0* 88,02,1* 87,03,3*

+ 91,04,0

90,03,1

90,04,1

87,02,5

86,04,5 86,03,5*

: (*) ( ,
) (<0,05).

62
. , ,
, - ,


, , ,
.
, , ,

, . , 3%.
,
, ,
, . ,

-
.
4 .

1.
(CD3+, CD4+, CD8+, CD19+),
CD4+/CD8+, .
.

M..

63

2. +
,
,
+ .
3.

.

[1] .., .., .., ..


. -: , 1993 - 223 .
[2] .., .., .. . . , 1999, - 8 .
[3] .., .., .. . : , 1999 - 135 .
[4] .. . -: , 1999 - 169 .
[5] .., .., ..
. ,
1998. - N4. - . 46-51

64

()


.. , .. , .. , .. ,
.. , ..

. ..


, () [4, 8, 9]. (-)
,
, , [7].
(- ) , ,
15 50 [5, 10].
-. , ,
[2, 6].
- ,
, ().
-

..

65

- [1, 3]. ( ), .

- .


.
, 10 ,
. .. .. .
30 20 30 .
( -), 3 .
(- ,
, , ).
, , , 6 .
(15 ) . (15 ) . 3 6
2- .
10 . (56-58-
) ,
, , -
,
, ( , ), ( ,
, ).
,
.

66
1. 58


. 1. , , 6 (40%) ( ), 5 (33,3%)

,
4 (26,7%) . 40% , , ( ), 6,7% ,
12,3% , 13,3% , 26,7% . ,
, , ,
(p = 0, 015).
.

(. 2). 2 ,

,

..

67

2.

:
1
1 3

5
1

( )

%:
25
25-50
>50
:

6
1
3
6
3
1

-,
( 25-30%),
, . , ,
( - ).

25-30%, , 1 .
, -.

68
3. ( %)
( +/- )

20 150 16 980

8587 2835

2828 1308

5979 2334

slg

128 60,3

262 106,7

53,5 11,1

54,8 74,6

528 150,4

368 83,8

169 52,5

335 106,5

383 102,7

708 586,7

107 20,9

152 23,0

28,614,3

83,444,0

6,204,90

26,416,4

14,113,3

2,850,74

3,542,63

12,011,1

: % ( )
( ) .


T- (CD4,
CD5, CD8, CD16, CD25, HLA-DR, )
IgA, slgA, IgM, IgD, IgE, IgG .
, , D8- T- ( 21,71,8 28,61,7%),
, , .
, CD8-cyo T-
. T- .
, , .
-
. . 3, , , 90%
IgM IgG .

..

69

,

- :
1. 25-30% : 3 10 6
14- .
2. 30% : I
, , 6 . .

1. -. , , , .
2. , ,
CD8- T-
IgM IgG .
3. 2
-.

[1] .., .., .., .. //


., 1993. . 42-47.
[2] .., .. // . . 1993. 4. . 7-9.
[3] ..
. . . ... . . . ., 1994.
[4] .., .., .. // . . 1988. 8. . 33-37.
[5] .., .., .. // . . 1989. 4. .
4345.

70




.. , ..
-
, ,

-
, .
, ,
.
, ,
, [1], , , .
. .
, ,
,
[1]. (GnRH) ,
.

. T- ,

.. , ..

71

[2]. ,
T-
[3],
.
-, (Ig) , , G,
, . ,
-, , . [4]. , IgG IgM.
IgM , IgG
, . , Ig IgG .

5 . ,
.. [4], , .

.
2
27-42 (
10 .). 2,5 5
, 2 3. 1 . (2,5 ) 2
. 3 . , : 1 . (500 )
5 .; -200 1 . (200 ) 40 .
10 .; 10 1 30 .
10 .

72
1.


/
, %

6 .

6 .

24,4

7,8

25,2

14,4

68

57

14 . ,
.
3 .
.
SA-600 (), 3,5 . 3
. :
1
3
67pD = V,

D ; V .
St. aureus. (), 2- 3-
(2 3) .
4- (4), 3c- IgA, IgG, IgM
; ,
() 6,3 4% .

.. , ..

73

2.

6,5 1,5

2,4 1,4

5,1 0,9

25050

16480

248100

10010

82,5 30

121,6 66

16 5,5

9,5 4,0

11,86

11242

77,9 40

77,9 40


11% ,
,
(. 1).
,
2 4 (. 2).
3, . 3-, , . ,
.

. ( ) .
. (. 3) , ,
,
IgA, [3].
IgG, IgM, .
.

74
3.

6500 250,0

4200 1000

5040 1100

, x10 /

3500 500

2360,9 800

3286,6 900

,%

59,5 12,5

52,711

57,4 6

,%

3,5 2,5

9,4 2,9

5,4 1,4

755

39,4 20

51,6 15

IgA

2,5 0,4

1,57 0,6

2,36 0,7

IgG

131,0

10,9 4,0

12,6 6,0

Ig

1,5 0,2

1,54 0,6

2,32 1,0

, x10 /
6

Ig , IgG IgM,
. ,
, , 2 ,
2, 3 4. 3 , .
IgG IgA , IgM ,
.
, . ( )
,
.
,
.

.. , ..

75

[1] A.M.
// . 1984. Ks . . 16-20.
[2] . : . . . /
.. , .. , .. , .. . ., 1984.
[3] A.M. - : . . ... . . . ,
1986.
[4] ..
. . . ... - .
. 1990.

76





(, , .)

1 , 12 . 1 /. 10
(12 . 1 )
,

10 1 . 1 /. 10
(1 . 10 )


(2 : , )
1 , 1 . 3 /. 10
(3 . 1 )

1 , 2 . 3 /. 10
( , ,
!)

1 , 1 . 3 /. 10
( ) (3 . 1 );
1 , 2 . 3 /. 10
( ) (6 . 1 ).


10 , 1 . 2 /. 2 3
3 (2 . 10 )

, 1 , 1 . 1 /.
10 (1 . 1 )
, 10 , 1 . 1 /.
10 (1 . 10 )
, 10 , 1 . 2 /.
10 (2 . 10 )

77
( )
1 , 2 . 3 /. 6
(4 . 1 )

10 , 1 . 12 /. 6
(12 . 10 ).


1 , 2 . 23 /. 10
(46 . 1 )
-
10 , 1 . 1 /. 10
(1 . 10 )


,

10 , 1 . 1 /.
3 7
14
(2 . 10 )

( 8- ) 10 , 1 . 1 /.
10
(1 . 10 ).

10 , 12 . 1 /.
10-20 (1-4 . 10 )

1 , 1 . 1 /.
10 (1 . 1 ).

-
10 , 1 . 1 /. 3
6-7 2
(2 . 10 ).

78


1 , 1 . 1 /. 10
(1 . 1 ).


1 , 2 . 23 /. 10
(46 . 1 )

10 , 1 . 1 /. 10
(1 . 10 ).

,



1 , 2 . 12 /. 10
(24 . 1 )

10 , 1 . 1 /. 10
(1 . 10 ).


10 , 1 . 1 /. 7 ,
2 .
23 .


1 , 2 . 23 /. 10
(46 . 1 )

10 , 1 . 1 /. 10
(1 . 10 ).


10 , 1 . 2 /. 10 ,
1 . 2 /. 10
(3 . 10 )

79

10 , 1 . 2 /. 20
(4 . 10 ).


1 , 1 . 2 /. 7-10
(2 . 1 )

10 , 1 . 2 /. 10
(2 . 10 )

10 , 1 . 1 /. 10-14
(12 . 10 )

III , ; 1 , 1 . 2 /
14
IIIIV , ; 1 , 1 . 2 /
1420 .



1 , 1 . 1 /. 10
(1 . 1 )

1 , 1 . 1 /. 10
(1 . 1 )

1 . 1 . 3 /. 10
(3 . 1 )

1 , 1 . 3 /. 20
(6 . 1 )

(, , , .)
1 , 1/2 . 2 /. 10
(1 . 1 )

80
, , , , (
). 221 20 1995 . (. . 95/211/4).
10 .
1 10 .
. ..
.. .


, 117997, . ,
. -, 16/10
./: (495) 330-74-56, 429-80-10, 429-77-40,
e-mail: zao-peptek@mtu-net.ru,
www.peptek.ru, www.likopid.ru.